Search Bar & Filters
Found 7 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the real-world effectiveness, safety, and patient compliance of ribociclib combined with an aromatase inhibitor for adjuvant treatment in patients with hormone receptor-positive, HER2-negative early breast cancer at high risk of recurrence. This observational study also compares ribociclib treatment with abemaciclib plus endocrine therapy and endocrine therapy alone, aiming to better understand treatment decisions and clinical adoption in routine practice. The study is conducted across breast centers and gynecological practices to represent typical healthcare settings. Participants receive treatment based on their physicians clinical judgment without randomization or intervention assignment. The study collects data from patients treated with ribociclib plus aromatase inhibitor with or without luteinizing hormone-releasing hormone LHRH, abemaciclib plus endocrine therapy with or without LHRH, or endocrine therapy alone with or without LHRH. Baseline data and follow-up information on adverse events, quality of life, treatment adherence, and socio-economic factors are gathered over time. During the study, participants undergo assessments including evaluation of invasive disease-free survival up to 36 months, quality of life questionnaires, medication adherence reports, and monitoring of adverse events and treatment changes. Data on reasons for treatment decisions, patient perceptions, and healthcare provider involvement are also collected. The study duration extends up to 39 months to provide a comprehensive overview of treatment impact and patient experience in real-world clinical settings.
Actively Recruiting
Researchers are evaluating how well once-weekly insulin icodec maintains blood sugar levels compared to daily basal insulin injections in adults with type 2 diabetes. The study focuses on people who need to start basal insulin treatment after using other glucose-lowering medications. This phase 4 trial aims to assess insulin icodecs effectiveness in real-world clinical practice over about 13 months. Participants will be randomly assigned to receive either weekly subcutaneous injections of insulin icodec or daily subcutaneous injections of basal insulin analogues such as insulin glargine, detemir, or degludec. The study compares these two insulin regimens as part of standard type 2 diabetes care. Treatment continues during the 52-week period to monitor blood sugar control and treatment satisfaction. Throughout the study, participants will undergo assessments including measuring changes in glycated hemoglobin HbA1c from baseline to week 52. They will also complete questionnaires on treatment adherence, satisfaction, and burden, and researchers will track severe hypoglycemia episodes and insulin doses. The trial spans about 13 months, providing thorough monitoring of treatment impact and safety in daily clinical use.
Actively Recruiting
Researchers are evaluating the effects of elecoglipron compared with a placebo in adults with chronic kidney disease CKD, including those with and without type 2 diabetes mellitus T2DM. This Phase III, randomized, double-blind, placebo-controlled study includes participants who are receiving standard care treatments for CKD, including the SGLT2 inhibitor dapagliflozin. The study aims to determine whether elecoglipron can reduce the risk of kidney function decline, end-stage kidney disease, and mortality. Participants will be randomly assigned to receive either elecoglipron tablets or matching placebo tablets once daily. The study is multicenter and involves parallel groups. The treatment period and evaluation are event-driven and may last up to 4.5 years. Both study groups will continue their background therapies for CKD alongside the study medication or placebo. During the study, participants will be monitored regularly to assess kidney function, cardiovascular events, and overall health outcomes, including mortality. Researchers will measure sustained declines in estimated glomerular filtration rate eGFR, occurrence of end-stage kidney disease, cardiovascular death, heart failure hospitalizations, and other related outcomes. The study includes safety monitoring throughout the trial, which is expected to last until October 2030, with participant involvement potentially extending up to 4.5 years.
Actively Recruiting
Researchers are evaluating the Accu-Chek SmartGuide continuous glucose monitoring CGM system and its predictive features in adults with type 1 diabetes or insulin-treated type 2 diabetes. The study aims to understand if using the Predict App alongside the CGM system affects fear of hypoglycemia, psychological well-being, sleep quality, confidence in preventing low blood sugar, and diabetes-related distress and empowerment. It also assesses changes in glucose levels and how participants respond to CGM alarms and trend information. Participants will use the Accu-Chek SmartGuide CGM system for 6 weeks. For the first 2 weeks, they will use the system without the predictive features. Then, they will receive training on the Predict App and use the system with predictive features enabled for the following 4 weeks. This study is conducted remotely with no in-person visits. During the study, participants will complete online questionnaires after 2 and 6 weeks and answer short questions twice daily using a smartphone app during the first and last 2 weeks. CGM data will be collected continuously to measure glucose ranges, variability, and mean levels. Additionally, a subgroup of 10 participants will be interviewed online about their experiences with the predictive features. The main outcome measured is the change in fear of hypoglycemia over the 4-week period using the Predict App.
Actively Recruiting
Cholangiocarcinoma is a rare and aggressive bile duct tumor with limited treatment options and a poor prognosis. Researchers are collecting real-world data on the use of the targeted drug ivosidenib in adults with locally advanced or metastatic cholangiocarcinoma who have an IDH1 R132 mutation and have already received at least one prior systemic therapy. This prospective, multicenter observational study in Germany aims to provide evidence on the effectiveness, quality of life, and safety of ivosidenib in a broad patient population. Ivosidenib will be given following the current summary of product characteristics SmPC. The study will observe patients treated with ivosidenib in routine clinical practice without altering their treatment. Data will be gathered over a maximum period of 38 months from first patient inclusion to last patient last visit, covering treatment duration and patient outcomes during this time. Participants will be monitored regularly to assess progression-free survival as the primary outcome, along with overall survival, response rates, adverse events, and quality of life measures related to cholangiocarcinoma. The study also collects information on dose modifications, treatment duration, previous therapies, concomitant medications, and physician treatment decisions. This observational study continues until December 2027, allowing long-term follow-up of patients receiving ivosidenib.
Actively Recruiting
Researchers are investigating mental health conditions such as distress, depression, anxiety, and eating disorders in people with diabetes. This study aims to use a personalized approach called precision mental health to identify subgroups of people with diabetes who share common patterns in the relationships between glucose levels and psychosocial factors. The goal is to develop a digital twin, a virtual model that can simulate and predict the course of mental health and blood sugar control to help guide more tailored diabetes care. Participants include over 1,800 people with type 1, type 2, or other specific types of diabetes. They continuously complete ecological momentary assessments EMA, which involve daily surveys about stress, mood, and diabetes distress, along with questionnaires every six months. Glucose levels are measured using continuous glucose monitoring CGM devices, and clinical interviews diagnose mental health disorders. Data on medication, complications, diet, physical activity, and metabolic measures like HbA1c are also collected to build comprehensive profiles. During the study, participants undergo repeated assessments every six months over a two-year period, including EMA, questionnaires, CGM data collection, and diagnostic interviews in a subset. Researchers analyze the complex interactions between metabolic, behavioral, and psychological data using machine learning to identify subgroups and validate the digital twins predictions. The main outcomes measured include the incidence and remission of mental disorders, diabetes distress, and glycemic control. This observational study will provide insights to support personalized mental health care in diabetes.
Actively Recruiting
Researchers are observing participants with Chronic Lymphocytic Leukemia CLL who are receiving venetoclax either alone or combined with rituximab, obinutuzumab, ibrutinib, or acalabrutinib. The study aims to assess the effectiveness, health-related costs, and participant-reported outcomes in real-life clinical settings, reflecting typical medical practice. This observational study is sponsored by AbbVie and involves patients treated according to local clinical guidelines. Participants are grouped based on their treatment regimen, including venetoclax alone or with one of the specified combination therapies. Treatments are prescribed at the physicians discretion and according to local labels, without experimental intervention from the study. The study captures data as patients receive their usual care with these therapies. During the study, participants responses to treatment are monitored, focusing on the best overall response rate within 12 months. Researchers collect health economic data and patient-reported outcomes to understand the impact of these treatment approaches in everyday practice. Participation involves observation and data collection without altering prescribed therapies, continuing until the study completion in December 2030.